ETHSX — Eaton Vance Worldwide Health Sciences Fund
Data updated: 2026-07-27
ETHSX — Eaton Vance Worldwide Health Sciences Fund. Global (incl. US) Large Cap Growth Health Care Equity. Holdings, fees, performance and SEC filings.
ETHSX Fund Overview
ETHSX — Eaton Vance Worldwide Health Sciences Fund is a US mutual fund managed by Eaton Vance Growth Trust, categorised as Global (incl. US) Large Cap Growth Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Eaton Vance Growth Trust
- Category: Global (incl. US) Large Cap Growth Health Care Equity
- Assets under management: $757.90M
- 1-year return: 5.7%
- Ticker: ETHSX
- SEC CIK: 0000102816
- SEC series ID: S000005202
- Share class ID: C000014191
ETHSX Holdings
Top 10 holdings of Eaton Vance Worldwide Health Sciences Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly & Co | 12.47% |
| AbbVie Inc | 6.46% |
| Johnson & Johnson | 6.45% |
| AstraZeneca PLC | 6.24% |
| UnitedHealth Group Inc | 5.49% |
| Roche Holding AG | 5.44% |
| Merck & Co Inc | 5.08% |
| Bristol-Myers Squibb Co | 4.25% |
| Vertex Pharmaceuticals Inc | 3.38% |
| Gilead Sciences Inc | 3.34% |
ETHSX Portfolio Allocation
Asset-class allocation of Eaton Vance Worldwide Health Sciences Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.4% |
| Cash & Equivalents | 0.3% |
ETHSX Performance
Total returns for ETHSX (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -6.1% |
| 1 year | 5.7% |
| 3 years (annualised) | 4.3% |
| 5 years (annualised) | 3.3% |
ETHSX Risk Information
Risk metrics for ETHSX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 13.6%
ETHSX Costs and Fees
ETHSX costs about $118 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.18%
- Gross expense ratio: 1.21%
- Portfolio turnover: 30%
- Brokerage commissions: 1.19 bps of average net assets (SEC N-CEN)
ETHSX Cashflows
Over the 12 months to 2026-05, Eaton Vance Worldwide Health Sciences Fund had net outflows of $93.10M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-05 | −$10.79M |
| 2026-04 | −$12.02M |
| 2026-03 | −$9.78M |
| 2026-02 | −$10.81M |
| 2026-01 | −$10.85M |
| 2025-12 | $41.08M |
ETHSX Debt Constituents
No individual debt constituents are reported in Eaton Vance Worldwide Health Sciences Fund's latest SEC N-PORT filing.
ETHSX Prospectus and SEC Filings
Official Eaton Vance Worldwide Health Sciences Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2025-12-23
- Prospectus (485BPOS) — filed 2024-12-23
- Prospectus (485BPOS) — filed 2023-12-21
- Portfolio holdings (N-PORT) — filed 2026-07-27
- Portfolio holdings (N-PORT) — filed 2026-04-24
- Portfolio holdings (N-PORT) — filed 2026-01-28
- Annual census (N-CEN) — filed 2025-11-12
- Annual census (N-CEN) — filed 2024-11-08
Related Funds
Other Global (incl. US) Large Cap Growth Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.